Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy?
J Neuropsychiatry Clin Neurosci
; 7(2): 135-44, 1995.
Article
em En
| MEDLINE
| ID: mdl-7626956
ABSTRACT
Two primary hypotheses have been proposed to explain the pathophysiology of the neuroleptic malignant syndrome (NMS) 1) that NMS is produced by abrupt and extensive central dopamine receptor blockade by neuroleptics, particularly in nigrostriatal and hypothalamic pathways; and 2) that NMS, like malignant hyperthermia (MH), results from a preexisting defect in skeletal muscle metabolism that is unmasked or provoked by neuroleptic exposure. To evaluate these models, the authors review studies published since 1980 of the clinical features, epidemiology, risk factors, laboratory assessment, and relevant animal models of NMS and MH. Data from these studies suggest that although NMS and MH are clinically similar, they are pharmacologically distinct, implying that cross-reactivity between triggering agents is unlikely to occur.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Antipsicóticos
/
Hipertermia Maligna
/
Síndrome Maligna Neuroléptica
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
J Neuropsychiatry Clin Neurosci
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Estados Unidos